Retrospective Comparison of Two Different Schedules of Irinotecan, 5-Fluorouracil and Folinic Acid in Previously Untreated Patients with Advanced Colorectal Carcinoma: A Single Institution Experience

References

• Parkin MD, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin Oncol 2005; 55: 74–108.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1996; 29A: 2077–792.
   Google Scholar
• The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.
   Google Scholar
• Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinothecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–260.
   PubMed Web of Science ®Google Scholar
• Lavrenkov K, Man S, Mermershtain W, Cohen Y. Retrospective comparison of single agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer. J Chemother 2002; 14: 84–87.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 543: 905–912.
   Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multi-centre randomised trial. Lancet 2000; 355: 1041–1047.
   PubMed Web of Science ®Google Scholar
• Sargent D, Niedzwiecki D, O'Connell M, et al: Recommendation for caution with irinothecan, fluouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144–145.
   PubMed Web of Science ®Google Scholar
• Rothenberg M, Meropol NJ, Poplin E, et al. Mortality associated with irinothecan plus bolus fluouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001; 19: 3801–3807
   PubMed Web of Science ®Google Scholar
• Elfring G, Emanuel D, Rostagi R, et al. Patterns of use and mortality in the community oncology practice setting among patients receiving first-line weekly bolus irinothecan/5-fluouracil/leucovorin (IFL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: abs. 530.
   Google Scholar
• Man S, Lavrenkov K, Gluzman A, et al. Chemotherapy with irinotecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study. J Chemother 2003; 15: 304–305.
   PubMed Web of Science ®Google Scholar
• Idelevich E, Man S, Lavrenkov K, et. al. Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treat-ment? J Chemother 2004; 16: 487–90.
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990; 8: 1935–1937.
   PubMed Web of Science ®Google Scholar
• Gandia D, Abigerges D, Armand JP, et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993; 11: 196–197.
   PubMed Web of Science ®Google Scholar
• Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high dose escalation using intensive high-dose lop-eramide to control diarrhea. J Natl Cancer Inst 1994; 84: 446–449.
   Google Scholar
• Therasse P, Arbuck S, Eisenhauer EA et al. New guide-lines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205–210.
   PubMed Web of Science ®Google Scholar
• Mantel L, Haenszel W. Statistical aspects of the analy-sis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–748.
   PubMed Web of Science ®Google Scholar
• Kaplan El, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
   Web of Science ®Google Scholar
• de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low dose leucovorin and fluouracil bolus with bimonthly high-dose leucovorin and fluouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808–815.
   PubMed Web of Science ®Google Scholar
• Maielo E, Giuliani F, Gebbia V, et al. FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Ocologico dell'Italia Meridionale(GOIM). Ann Oncol 2006; 17 (Suppl. 7); v1i55–v1i59.
   Google Scholar
• Köhne C-H, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluouracil plus folinic acid with or without irinotecan in patients with metastatic colorec-tal cancer: European Organization for Research and Treatment of Cancer. J Clin Oncol 2005; 23: 4856–4865.
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Eckardt JR, Kuhl JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recur-rent colorectal cancer. J Clin Oncol 1996; 14: 1128–1135.
   Google Scholar
• Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluo-rouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–260.
   Google Scholar
• Pitot HC, Wender DB, O'Connell MJ et al. Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 1997; 15: 2910–2919.
   Google Scholar
• Meta-analysis group in cancer. Efficacy of continuous infusion of fluorouracil compared with bolus administration in advanced colorectal carcinoma. J Clin Oncol 1998; 16: 301–308.
   Google Scholar
• Köhne C-H, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluo-rouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer 40952. J Clin Oncol 2003; 21: 3721-3728.
   Google Scholar